Allspring Global Investments
HRTX icon

Allspring Global Investments’s Heron Therapeutics HRTX Stock Holding History

Allspring Global Investments’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1
Closed -$1 – 2058
2024
Q3 		$1 Sell
1
-1,069
-100% -$2.55K ﹤0.01% 2442
2024
Q2 		$3.75K Buy
+1,070
New +$3.29K ﹤0.01% 2249
2023
Q4 		– Sell
-41,034
Closed -$42.3K – 2451
2023
Q3 		$42.3K Sell
41,034
-17,901
-30% -$25.5K ﹤0.01% 2319
2023
Q2 		$68.4K Buy
58,935
+27,223
+86% +$48.5K ﹤0.01% 2192
2023
Q1 		$47.9K Buy
31,712
+12,268
+63% +$30.7K ﹤0.01% 2300
2022
Q4 		$48.6K Buy
19,444
+14,601
+301% +$47K ﹤0.01% 2335
2022
Q3 		$20K Hold
4,843
– – ﹤0.01% 2624
2022
Q2 		$13K Sell
4,843
-69,673
-94% -$280K ﹤0.01% 2555
2022
Q1 		$426K Buy
74,516
+21,539
+41% +$158K ﹤0.01% 2287
2021
Q4 		$483K Buy
+52,977
New +$541K ﹤0.01% 2309

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Allspring Global Investments's HRTX Position: Q4 2024 in Review

Allspring Global Investments sold out of Heron Therapeutics (HRTX) in Q4 2024, closing a stake of 1 share — an estimated $1 sold.

Allspring Global Investments first reported a position in HRTX in Q4 2021 and held it in 10 quarters. The position peaked at $483K in Q4 2021. 161 funds tracked by Wall St. Rank hold HRTX as of Q4 2024.

  • Allspring Global Investments reported no remaining Heron Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Allspring Global Investments sold 1 Heron Therapeutics share in Q4 2024, an estimated $1.
  • Allspring Global Investments first reported a position in Heron Therapeutics in Q4 2021 and held it in 10 quarters.
  • Allspring Global Investments's Heron Therapeutics position peaked at $483K in Q4 2021.
  • 161 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2024.

Based on Allspring Global Investments's 13F filing for Q4 2024, filed 29 Jan 2025.